The multiple myeloma staging system is used to describe the severity of multiple myeloma based on various prognostic factors identified in various clinical research studies. Staging helps doctors to reckon disease prognosis and thus an appropriate treatment strategy can be adopted.
Revised International Staging System (RISS) is the most commonly used system for staging multiple myeloma.
Following table describes the characteristics of multiple myeloma according to different RISS stages:
|I||Serum beta-2 microglobulin <3.5 mg/L;|
Serum albumin level >/=3.5 g/dL;
Absence of high-risk cytogenetic abnormalities; and
Serum LDH level </= Upper limit of normal
|II||Neither Stage I nor Stage III|
|III||Serum beta-2 microglobulin >/=5.5 mg/L; and|
Either Presence of high-risk cytogenetic abnormalities; or
Serum LDH level > Upper limit of normal
Join our MULTIPLE MYELOMA COMMUNITY to connect with fighters and survivors across the globe.